A5082255545- Opioid Use Disorder Treatment
- Substance Abuse Treatment and Outcomes
- Pain Management and Opioid Use
- Neurotransmitter Receptor Influence on Behavior
- Forensic Toxicology and Drug Analysis
- Pain Mechanisms and Treatments
- Poisoning and overdose treatments
- Neuroscience and Neuropharmacology Research
- Prenatal Substance Exposure Effects
- HIV, Drug Use, Sexual Risk
- Neuropeptides and Animal Physiology
- Treatment of Major Depression
- Attention Deficit Hyperactivity Disorder
- Tryptophan and brain disorders
- Pharmacological Receptor Mechanisms and Effects
- Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Stress Responses and Cortisol
- Resilience and Mental Health
- Cannabis and Cannabinoid Research
- Biochemical Analysis and Sensing Techniques
- Schizophrenia research and treatment
- Smoking Behavior and Cessation
- Anesthesia and Sedative Agents
- Neuroinflammation and Neurodegeneration Mechanisms
- Mental Health Research Topics
Columbia University
2015-2024
Columbia University Irving Medical Center
2016-2024
New York State Psychiatric Institute
2011-2024
Royal College of Physicians
2024
Columbia College
2024
New York Psychoanalytic Society and Institute
2015-2023
New York City Department of Health and Mental Hygiene
2016
National Center on Addiction and Substance Abuse at Columbia University
2011-2014
New York State Office of Alcoholism and Substance Abuse Services
2011-2014
American University
2005-2009
Glial activation is hypothesized to contribute directly opioid withdrawal. This study investigated the dose-dependent effects of a glial cell modulator, ibudilast, on withdrawal symptoms in opioid-dependent volunteers after abrupt discontinuation morphine administration. Non-treatment-seeking heroin-dependent (n = 31) completed in-patient, double-blind, placebo-controlled, within-subject and between-group study. Volunteers were maintained (30 mg, QID) for 14 days placebo (0 last 7 3-week...
<h3>Importance</h3> Buprenorphine is an efficacious, widely used treatment for opioid use disorder (OUD). Daily oral transmucosal formulations can be associated with misuse, diversion, and nonadherence; these limitations may obviated by a sustained release formulation. <h3>Objective</h3> To evaluate the ability of novel, weekly, subcutaneous buprenorphine depot formulation, CAM2038, to block euphorigenic effects suppress withdrawal in non–treatment-seeking individuals OUD. <h3>Design,...
The characteristics of patients with co-occurring chronic pain and prescription opioid abuse have not been well described, even less is known about differences between men women in this population.This study evaluated sex the demographic, diagnostic, behavioral attributes abuse.Data were collected via self-report semistructured clinical interviews from 162 (120 42 women) who screened for a investigating liability opioids.There no age, race, education, marital status, or employment status....
Providing take-home naloxone (THN) to people who use opioids is an increasingly common strategy for reversing opioid overdose. However, implementation hindered by doubts regarding the ability of administer and respond appropriately overdoses. We aimed increase understanding competencies required demonstrated users had recently participated in a THN programme were subsequently confronted with overdose emergency.
Few studies have examined abuse of prescription opioids among individuals with chronic pain under buprenorphine/naloxone (Bup/Nx) maintenance. The current 7-week inpatient study assessed oral oxycodone self-administration by patients who had a history opioid abuse. Participants (n=25) were transitioned from their preadmission prescribed to Bup/Nx. All the participants tested each sublingual Bup/Nx maintenance doses (2/0.5, 8/2 or 16/4 mg) in random order. During period, could self-administer...
Opioid-related overdose deaths in North America have increased drastically, partially due to the prevalence of illicitly manufactured fentanyl. The current study sought assess and intentionality fentanyl use among individuals with opioid disorder (OUD).For this secondary analysis (study 1) we screened a total 1118 urine samples from 316 participants OUD 2016 2019. Fentanyl knowledge were assessed separate sample 2; N = 33).In 1, 34.6% all tested positive for Overall, 149 (47.2%) provided...
To examine whether tamper-resistant formulations (TRFs) of tapentadol hydrochloride extended-release (ER) 50 mg (TAP50) and 250 (TAP250) could be converted into forms amenable to intranasal (study 1) or intravenous abuse 2).Randomized, repeated-measures study designs were employed. A non-TRF OxyContin® 40 (OXY40) served as a positive control. No drug was taken in either study.The studies took place an out-patient setting New York, NY.Twenty-five experienced, healthy ER oxycodone abusers...
Background and Objectives While research on the separate relationships between health‐related quality of life (HRQOL) chronic pain, HRQOL opioid abuse has been sparse, even less work investigated factors associated with in individuals who have both pain meet criteria for use disorder. The data presented this analysis should allow a better understanding important to among dual‐diagnosed population. Methods Individuals dual diagnoses disorder were recruited clinical studies at Columbia...
In spite of the clinical utility buprenorphine, parenteral abuse this medication has been reported in several laboratory investigations and real world. Studies have demonstrated lower liability buprenorphine/naloxone combination relative to buprenorphine alone. However, research not yet examined combined formulation deter intranasal use a buprenorphine-maintained population. Heroin-using volunteers (n = 12) lived hospital for 8-9 weeks were maintained on each three sublingual doses (2, 8, 24...